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SINTESIS, PENCIRIAN DAN PENILAIAN BIOSERASI NANOPARTIKEL 
TERBITAN NATRIUM ALGINAT DISULFIDA BERANGKAI SILANG 
UNTUK PENYAMPAIAN DRUG KE KOLON 
 
ABSTRAK 
 
Penyampaian drug bersaiz nano khusus kepada kolon ialah sistem yang 
mencabar bagi sesuatu drug untuk sampai ke tapak sasaran kolon tanpa sebarang 
pembebasan di perut dan usus kecil. Penggunaan lapisan-demi-lapisan (LbL) pada 
salutan di permukaan nanopartikel telah meningkatkan penyampaian drug yang 
ketidaklarutan air secara oral ke kolon. Dalam kajian ini, kami mensasarkan untuk 
menghasilkan natrium alginat (SA) berangkai-silang disulfida berasaskan sisteamina 
dengan fabrikasi (LbL) untuk memperbaiki penyampaian paklitasel ke sel-sel kanser 
kolon secara kemoterapi oral. Sisteamina dikonjugasikan dengan tulang belakang SA 
yang teroksida untuk membentuk teras penswapasangan nanosfera berangkai-silang 
disulfida. Lima formulasi terbentuk, P1DL-P5DL dan disahkan oleh analisis Raman. 
P3DL telah dipilih untuk muatan paklitasel dan fabrikasi (LbL) dengan poli(alilamina 
hidroklorida) (PAH) dan poli (asid 4-stirenasulfonik asid-ko-maleik) garam natirum 
(PSSCMA) setelah menunjukkan keputusan yang memberangsangkan dari kajian 
pencirian dan pembebasan drug. Nanosfera P3DL muatan paklitasel yang difabrikasi, 
P3DL/PAH/PSSCMA telah menunjukkan kecekapan enkapsulasi sebanyak 77.1 % 
dengan kumulatif pelepasan drug sebanyak 45.1 %. Analisa sebaran cahaya dinamik 
(DLS) menunjukkan nilai pada 173.6 ± 2.5 nm dengan indeks kepoliserakan pada 
0.394 ± 0.105 dan potensi zeta pada -58.5 mV. Analisa TEM dan SEM menunjukkan 
nanopartikel dalam bentuk sfera. Dalam kajian kepekaan pH (pH 1 hingga 7), 
 
 
 
 
xvii 
 
peningkatan saiz sebanyak 102.2 % menunjukkan bahawa peralihan 
P3/PAH/PSSCMA adalah bergantung kepada pH. Sementara itu, saiz 
P3/PAH/PSSCMA meningkat sebanyak 33.0 % dalam kajian pengurangan-responsif 
selepas diinkubasi dalam 10 mM glutationa (hari ke-7). HT-29 menunjukkan daya 
hidup yang tinggi (86.7 %) selepas dirawat oleh nanosfera pada kepekatan 50 μg/mL 
dan dianggap sebagai mengalakkan pembawa nano dalam penyampaian drug ke kolon. 
Lebih daripada 70 .0 % nanosfera terfabrikasi telah diserap masuk ke dalam sel-sel 
HT-29, dan ini menunjukkan proses kemasukan selular ke dalam sel-sel kanser telah 
berjaya. Oleh itu, natrium alginat berangkai-silang disulfida terfabrikasi ini boleh 
dianggap sebagai pembawa nano yang berpotensi untuk penyampaian kemoterapeutik 
khusus ke kanser kolon.  
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SYNTHESIS, CHARACTERISATION AND EVALUATION OF 
BIOCOMPATIBLE DISULPHIDE CROSS-LINKED SODIUM ALGINATE 
DERIVATIVE NANOPARTICLES FOR COLON TARGETED DRUG 
DELIVERY 
 
ABSTRACT 
 
Colon specific nano-drug delivery is a challenging system for a drug to reach 
the colon target site without any release along the stomach and small intestines. The 
application of layer-by-layer (LbL) on nanoparticles surface coating has been applied 
to improve the colon targeted oral drug delivery of insoluble drugs. Here, we aimed to 
formulate a self-assembly cysteamine-based disulphide cross-linked sodium alginate 
(SA) (with LbL) to improve the delivery of paclitaxel to colonic cancer cells to 
promote oral chemotherapy. Cysteamine was conjugated to the backbone of oxidised 
SA to form a core of self-assembly disulphide cross-linked nanospheres. Five 
formulations were formed, P1DL-P5DL and verified by Raman analysis. P3DL was 
chosen for paclitaxel loading and fabricated (LbL) with poly(allylamine 
hydrochloride) (PAH) and poly (4-styrenesulfonic acid-co-maleic acid) sodium salt 
(PSSCMA) after showing promising results from the characterisation and drug release 
studies. P3DL fabricated paclitaxel loaded nanospheres, P3DL/PAH/PSSCMA 
exhibited an encapsulation efficiency of  77.1 % with cumulative drug release of 45.1 
%. Dynamic Light Scattering (DLS) analysis was reported at 173.6 ± 2.5 nm with 
polydispersity index of 0.394 ± 0.105 and zeta potential of -58.5 mV. TEM and SEM 
analyses exhibited spherical shapes of nanoparticles. P3DL/PAH/PSSCMA was pH- 
 
 
 
 
xix 
 
dependent swelling transition from the pH sensitivity study (pH 1 to 7, increase of 
102.2 %). Meanwhile, the size of the nanospheres increased 33.0 % in reduction-
responsive study after incubating in 10 mM glutathione (day 7). The HT-29 cells 
showed high viabilities (86.7 %) after been treated with the nanospheres at 50 
µg/mL.and therefore, it was regarded as promising nanocarrier in colon drug delivery. 
More than 70.0 % of the fabricated nanospheres were uptaken in the HT-29 cells, thus, 
suggesting successful cellular internalisation process in the cancer cells. Therefore, 
this fabricated disulphide cross-linked sodium alginate nanospheres may be considered 
as a potential nanocarrier for colon cancer targeted chemotherapeutic drug delivery.   
 
 
 
 
1 
 
CHAPTER ONE 
 
 
INTRODUCTION 
 
 
 
1.1 Research background 
 
In the recent years, many researchers have shown interest in the development and 
innovation of colon targeted drug delivery system. The colon drug delivery system 
provides potential solutions for many diseases such as inflammatory bowel diseases, 
specifically Crohn’s disease, ulcerative colitis and colorectal cancer (Sreelatha and 
Brahma, 2013).  In addition, it provides a wide range of potential treatment for 
systemic diseases and applications in the delivery of peptides and vaccines into the 
human body (Saphier et al., 2012). Colon drug delivery system facilitates the amount 
of drugs that are able to be delivered to the colon disease region successfully by 
minimising any adverse effects. This system gives high retention time for drugs to 
localise in the colon which would improve the absorption of the drugs into the human 
body (Sreelatha and Brahma, 2013). For colon drug delivery, oral route is preferable 
and most convenient route of administration due to its flexibility (Deng et al., 2015) 
and improvement of patient’s compliance (Sosnik, 2014). 
 
The different pH values along the gastrointestinal tract (GI tract) is one of the greatest 
obstacles for drugs to reach the target sites accurately  (Chang et al., 2012 ; Huang et 
al., 2015). Many strategies related to colon specific drug delivery were introduced, ie. 
covalent linkage between drugs and polymers (pro-drug), pH, time and microbial 
responsive strategies (Tiwari et al., 2010), osmotic pressure controlled drug delivery 
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system and also the use of multiparticulate systems such as microspheres and 
nanospheres (Agarwal et al., 2015).  
 
The human colon contains abundance of bacterial populations that are able to produce 
reducing environment for many chemical bonds like azo, nitro and disulphide bonds 
(Saphier et al., 2012). The polymers with disulphide bonds are widely investigated due 
to their stability in extracellular fluids compared to intracellular fluids with glutathione 
(GSH). The GSH functions as reducing atmosphere for disulphide linkages (Chang et 
al., 2012). In cancer cells, the concentration of GSH is four times higher than normal 
cells. For this reason, the introduction of disulphide cross-link in polymers could be a 
viable alternative strategy in colon cancer drug delivery studies (Gao et al., 2014).  
 
 
 
To date, there are varieties of nano carriers used in drug delivery system. 
Polysaccharide-based nanoparticles such as alginate play a vital role due to the  
qualities and favourable results as carrier for several anticancer drugs (Martinez et al., 
2012). Originated from brown algae, alginate consists of d-mannuronic acid (M) and 
l-gluronic acid (G) residues and bonded linearly by 1, 4-glycosidic linkages (Zhao et 
al., 2012). It is biodegradable, biocompatible, non-toxic, (Chang et al., 2012) and 
possess mucoadhesive properties (Hauptstein et al., 2015).  
 
Nanotechnology has also become a promising tool in improving therapeutic outcomes 
by focusing the delivery of drugs to the target sites to minimise drug accumulation at 
non-specific sites (Wang et al., 2010).  New system and technologies are required to 
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be developed and explored in overcoming current limitations in colon targeted drug 
delivery system. The therapeutic efficacy of the drug carriers could be improved and 
the undesirable adverse effects could be minimised via modification of the 
nanoparticles’ features (Lim et al., 2013). 
 
In this research, a novel biodegradable nanosphere derived from thiolated sodium 
alginate was synthesised to improve the delivery of the hydrophobic drug, paclitaxel 
to colonic cancer cells. Sodium alginate was first oxidised using sodium periodate 
prior to addition of cysteamine hydrochloride to modify the backbone of the sodium 
alginate. The disulphide cross-linked nanospheres were then produced by self-
assembly technique via the oxidation of thiol groups from cysteamine. Layer by layer 
(LbL) surface modification was conducted using polyelectrolytes; poly (allylamine 
hydrochloride) (PAH) and poly (4-styrenesulfonic acid-co-maleic acid) sodium salt 
(PSSCMA) to control the drug release of paclitaxel. The characterisations, pH 
sensitivity, reduction response, in vitro drug release, cytotoxicity and cellular uptake 
for paclitaxel loaded nanospheres were further investigated. In this study, pH 
sensitivity and reduction responsive environments play a major role to ensure the 
release of drug at the cancer target site.  
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1.2 Objective 
 
The main objective of this research is to develop a novel biodegradable thiolated 
sodium alginate derived nanospheres with surface modification to improve the 
delivery and release of paclitaxel to the targeted site of colonic cancer cells.  
 
The sub-objectives are: 
 
 
a) To synthesise thiolated sodium alginate by applying different ratios of oxidised 
sodium alginate and cysteamine hydrochloride. 
b) To assess and characterise the self-assembly of thiolated sodium alginate into 
nanospheres. 
c) To fabricate the nanospheres with Layer by layer (LbL) assembly technique 
using synthetic polyelectrolytes: poly (allylamine hydrochloride) (PAH) and 
poly (4-styrenesulfonic acid-co-maleic acid) sodium salt (PSSCMA).  
d) To determine the drug release of paclitaxel, cytotoxicity profile and cellular 
uptake of the nanospheres in colon cancer cells (HT-29).  
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CHAPTER TWO 
 
 
LITERATURE REVIEW 
 
 
 
 
2.1 Drug delivery 
 
Drug delivery has received great attention nowadays due to its benefits in cancer 
therapy treatment. Cancer is recognised as one of the leading causes of death around 
the world. This issue has been declared as one of the public health problems due to the 
outrageous number of patients increased day by day (Jain et al., 2016). Therefore, 
many researchers have conducted studies on the drug delivery systems that could be 
helpful for the development of innovative targeted therapies (Iglesias et al., 2012).  
 
The main purpose of drug delivery technology is to ensure therapeutic amount of drug 
is able to be delivered at the target site within the specific time. However, almost all 
chemotherapy drugs do not have this property (Wang et al., 2010). Due to this,  
significant efforts are needed to improve the delivery of anticancer drugs to the tumour 
cells (Iglesias et al., 2012) and reduce undesirable side effects to other non-targeted 
tissues or cells in the human body (Cortez et al., 2006; Sreelatha and Brahma, 2013; 
Deng et al., 2015). Many approaches have been reported to discover the best 
formulation to enhance the drug uptake by cancer cells. Therefore, it is really crucial 
to choose the right carrier for drug delivery system in order to ensure the 
pharmacological and pharmacokinetics of the selected drugs could be improved as 
compared to the ‘free’ drug alone (Hauptstein et al., 2015). 
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The colon specific drug delivery system is highly useful for the treatment of local and 
systemic diseases. Examples of local targeting diseases are Crohn’s disease, ulcerative 
colitis, irritable bowel syndrome, colorectal cancer and constipation. For systemic 
diseases, the delivery of peptides and vaccines such as insulin and typhoid are able to 
treat diabetic and typhoid fever respectively (Singh and Khanna, 2012; Sreelatha and 
Brahma, 2013). In colon cancer drug delivery, the drug should be protected until it 
reaches the target site. This means the drug release should neither occur in stomach 
nor small intestine. Further this, the drug should be degraded at the dissolution sites 
and be absorbed once it reaches the colon (Prasanth et al., 2012).   
 
There are two main routes of administration for colonic delivery; oral and direct 
(rectal) administration. However, for direct administration, only small amount of drug 
is able to reach the target site due to the presence of splenic flexure at transverse colon 
(Tiwari et al., 2010). Moreover, this method is not convenient and may not be 
acceptable by the patients (Lau and Lim, 2016). In cancer treatment, most patients 
prefer oral drug administration (Singh and Khanna, 2012; Anitha et al., 2014; Lau and 
Lim, 2016) compared to parenteral administration (intravenous and intramuscular) 
(Deng et al., 2015). This is because oral administration does not bring any harm or 
pain to the tissue during injection process and require less supervision, subsequently 
increases patients’ compliance and decreases the cost in hospital (Fox et al., 2015). 
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2.2 Colon cancer 
 
In 2015, colon or colorectal cancer is the third most leading causes of mortality among 
cancer patients worldwide after lung and female breast cancer. It has been reported 
that 1.36 million new incident cases with more than half a million deaths every year. 
More than 55% cases are diagnosed in developed regions and the highest rates are in 
Australia and New Zealand with elderly over 69 years old the main target (Lin et al., 
2015).  
 
Colon cancer cases have been reported in the United States since early 1940 (Siegel et 
al., 2014). Based on the research conducted by American Cancer Society, the number 
of new cases would increase up to 27 million in 2050 (Pourjavadi et al., 2014). Colon 
cancer cells are able to grow in the human body over 10 to 15 years. This cancer is 
often initiated from a group of benign adenomas, noncancerous colonic polyps. About 
10% of these adenomas will develop and change into cancer cells caused by mutation 
factors in tumour suppressors, apoptotic genes and also oncogenes. Many colon cancer 
survivors have to cope with long term sequence of treatments due to the possibility of 
relapse (Lin et al., 2015).  
 
There are several ways to treat colon cancer such as surgery, radiation therapy, 
chemotherapy and radiofrequency ablation. Chemotherapy is usually used as an 
immediate treatment alone or together with surgery or radiotherapy. Surgical resection 
with chemotherapy utilises either drug or combination of drugs are suitable for the 
current treatment based on the stage of the disease (Anitha et al., 2014). Nevertheless, 
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only 30% of the cases give good response in this treatment. Most treatments failed due 
to the development of tumour resistance cells and inability of drugs to distinguish 
between the tumour and normal cells within the body (Iglesias et al., 2012). As a result, 
this condition affects the healthy cells and develop undesirable side effects due to the 
high toxicity possessed by anticancer drugs (Jain et al., 2016). Some of the adverse 
effects from this treatment are neutropenia, anaemia, hand-foot syndrome, diarrhoea, 
gastrointestinal toxicity, mucositis, nausea, vomiting, fatigue, haematological disorder 
and liver toxicity (Lin et al., 2015). 
 
2.3 Anatomy of colon 
  
 
The gastrointestinal tract (GI tract) consists of several parts of organ from mouth to 
anus (Figure 2.1). The digestive system is responsible in taking food, digesting it to 
gain energy and nutrients and also eliminating waste through faeces. There are two 
major parts of lower abdomen in digestive system namely stomach and intestine. The 
intestine consists of small and large intestine (Sreelatha and Brahma, 2013).  
 
The small intestine divides into duodenum, jejunum and ileum which function to 
absorb nutrients and minerals from food. The colon is located at the distal end of the 
GI tract and comprised of caecum, ascending, transverse, descending segments and 
sigmoid region (Sreelatha and Brahma, 2013). This part plays a major role in 
extracting water and salt from solid wastes, storing wastes, absorbing some vitamins 
and an ideal site for microflora aided in fermentation process (Cummings and 
MacFarlane, 1991; Sreelatha and Brahma, 2013). The small intestines have higher 
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absorption capacity with 6.0 m length and ~120 m2 surface area as compared to colon 
(1.5 m length and 0.3 m2 surface area). Therefore, this unique physiological properties 
of the GI tract has become the major challenge for researchers to ensure the specific 
drug reaches the target site without any premature drug release either in stomach or 
small intestine (Chang et al., 2012). The summary of physiological properties for GI 
tract are stated in Table 2.1 (Prasanth et al., 2012 ; Lu et al., 2016).  
 
 
 
Figure 2.1: The gastrointestinal tract (GI tract) of human (Yousef et al., 2012). 
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            Table 2.1: The physiological properties of the GI tract. 
 
 
 
 
However, there are several factors that influence and affect the physiological pH in the 
gastrointestinal fluid such as the food intake and the disease, for example, in colon 
cancerous environment, the pH might become slightly acidic with values between 4.0 
to 5.0 (Gao et al., 2014).  In addition, at the colon entrance, pH would drop due to the 
presence of short chain fatty acids arising from bacterial fermentation of 
polysaccharides. There are more than 400 distinct species of microflora colonic 
bacteria that are able to produce large amount of lactic acid contributing to the decrease 
of pH in the colon (pH 5.0) (Prasanth et al., 2012).   
 
 
 
2.4 Paclitaxel as chemotherapeutic drug 
 
 
Paclitaxel (PCX) is one of the chemotherapeutic drugs that has been widely used to 
treat various types of cancers such as colon (Wang et al., 2010), head and neck cancers, 
multiple myeloma, melanoma and Kaposi’s sarcoma (Smitha et al., 2013), ovarian 
cancer, advanced breast cancer and non-small-cell lung cancer (Szczepanowicz et al., 
2016). PCX is derived from the taxane group and isolated from the bark of Taxus 
brevifolia. The mechanism of action for this antimitotic drug is to disrupt the 
Organ pH Transit Time Bacteria Count 
CFU/mL 
Stomach 1.0-3.5 >3 102-104 
Small intestine 6.5-7.4 3-4 103-104 
Large intestine 6.0-8.0 >20 1011-1012 
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microtubules system in the cell cycle during the late of G2 and M phase by inhibiting 
the cell from undergo replication process (Danhier et al., 2009). PCX will bind 
specifically at the β tubulin, a subunit of microtubule that causes total disruption in 
cell division process and leads to cell death (Kumari et al., 2010).  
 
To date, there are only a few formulations of PCX available in the market, eg.  the 
paclitaxel albumin-bound nanoparticles, approved by the Food and Drug 
Administration (FDA) for the treatment of breast and lung cancers (Ma and Mumper, 
2013). The limitation of the PCX formulation is due to poor water solubility, which is 
approximately less than 1 µg/mL (Koo et al., 2013). PCX is solubilised with the 
mixture of Cremophor EL and dehydrated ethanol (1:1) v/v in  intravenous 
administration to improve the bioavailability of  PCX (Wang et al., 2010 ; Koo et al., 
2013). However, few adverse effects were reported by the patients including 
hypersensitivity (Szczepanowicz et al., 2016), neurotoxicity (Koo et al., 2013), 
nephrotoxicity, vasodilatation on vascular muscle, laboured breathing, lethargy and 
hypotension (Danhier et al., 2009).  
 
Due to this, it is very crucial to find solution to overcome the poor water solubility of 
PCX and its non-specific mechanism of attacking both normal and cancer cells (Smitha 
et al., 2013). These problems could be solved through the formulation of a carrier or 
vehicle, which delivers the PCX into the cancer cells. The development of drug carrier 
formulation is important to optimise the PCX antitumour activity and minimise its 
adverse effects (Szczepanowicz et al., 2016). The encapsulation of PCX in the 
nanoparticles, made from biodegradable and non-toxic elements may protect the 
 
 
 
 
12 
 
human body from any side effects and toxicity caused by the drug.  (Ma and Mumper, 
2013).  
 
2.5 Nanoparticles in drug delivery 
 
The nanotechnology system for drug delivery research was explored in the late 1970s 
(Lim et al., 2013). This system has been broadly used in various applications like fibre, 
textiles, agriculture, forensic science, space and medical therapeutics (Kumari et al,. 
2010) due to distinctive properties that meet good criteria for many applications and 
the needs from the market (Rao and Geckeler, 2011). Nanoparticles are defined as 
solid and colloidal particles between the range from 10 to 1000 nm (Rao and Geckeler, 
2011; Iglesias et al., 2012) which offer many advantages in drug delivery compared to 
conventional approaches. Currently, numerous biodegradable polymers have been 
developed as nanocarriers to deliver the therapeutic of various water soluble, insoluble 
medicinal drugs and bioactive molecules. Nanocarriers are able to solubilise 
hydrophobic anticancer drugs by integrating with different water soluble compounds 
other than toxic organic solvent (Zhao et al., 2015 ;  Liu et al., 2016). 
 
Nanoparticles are categorised as nanospheres or nanocapsules based on their structure. 
The matrix for nanospheres is entirely mass and solid. The drug molecules are usually 
adsorbed on the surface or encapsulated within the particles. Meanwhile, nanocapsules 
contain a vesicular system that acts as a reservoir to entrap drugs or other substances 
in the centre. The drugs are restrained in a cavity at the core of the particles and 
surrounded by a solid material shell (Rao and Geckeler, 2011). Both of these distinct 
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architectures have their own benefits as nanocarriers in delivering bioactive 
compounds to the target site in human body (Zhao et al., 2015).      
 
The main aim for synthesising the nanoparticles is to create safe and effective drug 
carriers that deliver drugs more precisely to the tumour cells and maintain a therapeutic 
concentration over an extended period (Iglesias Teij et al., 2012; Lim et al., 2013). 
The selection of materials in the formulation of nanoparticles becomes a crucial factor 
in determining the success of delivering drugs to the colon target site (Soni et al., 
2010). In addition, the nanoparticles must be able to protect the drugs from premature 
degradation due to the interaction with different challenging biological conditions 
caused by enzymes and harsh pH environments in the GI tract to accomplish 
intracellular penetration at the specific site (Kumari et al., 2010).  Therefore, the 
surface modification of the nanoparticles with distinct physicochemical properties is 
important in order to facilitate the nanoparticles penetrate into the mucus barrier at 
colon cancer site (Lu et al., 2016). 
 
The strategy based on enhanced permeability and retention effect (EPR) phenomenon 
is widely exploited for passive delivery of nanoparticles into cancer target site. The 
first phenomenon was reported in 1986 involving new vasculatures formation at the 
cancer site and directly stimulated the extravasation and permeability of nanoparticles 
to the cancer cells (Jain et al., 2016 ; Lu et al., 2016).  In addition, the lack of lymphatic 
drainage at the cancer site enables accumulation and retention condition for 
nanoparticles (Szczepanowicz et al., 2016). For colon cancer, the cancer cells will 
invade and destroy the several layers of colon including mucosa, submucosa, 
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muscularis and serosa.  Therefore, the EPR effects will enable the nanoparticles to 
retain at the cancer site (Lu et al., 2016). Furthermore, the small diameter of the 
nanoparticles create more vulnerable condition for nanoparticles to accumulate at the 
inflamed or cancer colonic region due to pathophysiological changes in cancer cells 
like increase in mucus production, mucosal surface alterations crypt distortions and 
ulcers. These conditions occurred with the companion of a disrupted intestinal barrier 
and infiltration of immune related cells such as macrophages, lymphocytes and 
dendritic cells (Beloqui et al., 2014).   
 
2.5.1 Surface modification of nanoparticles 
 
There are abundant of developed nanoparticles formulations in drug delivery research. 
Various new formulations (particle size, permeability and release profile) of the 
selected polymers are enhanced to ensure their compatibility meet with the specific 
needs. However, these approaches are still facing some limitations.  Therefore, surface 
modification technique is introduced to enhance the function of the nanoparticles by 
presenting a new targeting group on its surface. This is important for an effective 
cancer treatment because the drugs must precisely reach at the cancer cells and retain 
in a therapeutic concentration over an extended period of time (Lim et al., 2013).  
Polyelectrolytes multilayers (PEMs) consist of different deposition charged layers 
onto the surface of the spherical core carrier. This sequential adsorption of 
polyelectrolytes has become one of the most versatile methods of forming nanocarriers 
(Szczepanowicz et al., 2016). There are ionic interactions formed between these two 
oppositely charged polyelectrolytes in an aqueous solution (Deng et al., 2015). This 
system was introduced in 1991 by applying various modification theories such as 
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electrostatic interactions, hydrogen bonding, hydrophobic interactions, covalent 
bonding, and corresponding based pairing (Wang et al., 2007).  
 
The PEMs system is purposely constructed as a diffusion barrier to the selected 
encapsulated drug and further control the drug release with desired rate and period at 
a specific time (Nugraha et al., 2014; Zhou et al., 2014).  This technology has been 
applied to oral drug delivery in improving the features of selected polymers to provide 
immediate respond towards the surrounding environment and increase drug uptake at 
the target site (Fox et al., 2015). This system can be used to design for both reservoir 
and matrix nanoparticles drug delivery system which provides an ability to increase 
duration of time for polyelectrolyte nanoparticles remain in the blood circulation 
(Szczepanowicz et al., 2016). It also facilitates EPR phenomenon based on passive 
diffusion to the interstitial cancer target site with the nano-size ~100 nm particles 
(Ramasamy et al., 2014).  
 
There are several polyelectrolytes used in the surface modification of nanoparticles. 
The examples for standard synthetic pairs of polycations and polyanions are 
poly(allylamine hydrochloride) (PAH) and poly(acrylic acid) (PAA) (Guo et al., 
2015); polyethyleneimine (PEI) and  poly(styrene sulfonate) (PSS) (Warszynski et al., 
2015). Both cations (positive) and anions (negative) surface charge of the 
nanoparticles show their own distinctive characteristics in improving the drug delivery 
treatment. For instance, the positively surface charged nanoparticles adhere to 
inflamed tissue in bowel diseases more easily due to the negative charge on the 
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intestinal mucosa surface. Meanwhile, the negatively surface charged nanoparticles 
are able to inter-diffuse among the mucus network due to less electrostatic interaction 
formed between them. Therefore, the nanoparticles would preferentially adhere to the 
inflamed colon via electrostatic interaction with the presence of positively charged 
proteins (cytokines) in colorectal cancer site (Lu et al., 2016).   
 
2.6 Polysaccharides in colon drug delivery  
 
Natural polymers especially polysaccharides have been chosen as nanocarrier for 
colon drug delivery due to the benefits (Iglesias et al., 2012). Most of the 
polysaccharides are known as “generally regarded as safe” (GRAS). These polymers 
are found originated from plants (guar gum, inulin and pectin) while chitosan, 
chondroitin sulphate are derived from animals (Tiwari et al., 2010). The alginate and 
dextran are originated from algae and microbes respectively (Philip and Philip, 2010).  
 
Polysaccharides contain reactive groups such as carboxyl, hydroxyl and amino groups, 
making it suitable to undergo multiple modifications for drug delivery study (Zhao et 
al., 2015). Modified polysaccharides possess excellent characteristics in 
biodegradability, biocompatibility (Philip and Philip, 2010 ; Tiwari et al., 2010) high 
stability, low toxicity, non-immunogenicity (Zhao et al., 2015) and better 
mucoadhesive property (Yaser et al., 2016). Further this, the polymers also play a 
major role in food industries (Kaur et al., 2012) due to their abilities as binders, 
thickeners, emulsifiers and gelling agents (Sharma and Ahuja, 2011).  
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The process of fixing two surfaces is known as adhesion. Mucoadhesion is referring 
to adhesion that occurs in mucosal membrane (Sharma and Ahuja, 2011). Since 1980s, 
mucoadhesive polysaccharides are known as potential excipients to prolong the 
duration of contact time by increasing the drug concentration at the absorption site to 
improve the cellular uptake (Hauptstein et al., 2015) on all the mucosal membrane 
surfaces (gastrointestinal, nasal, pulmonary, ocular, buccal, rectal and vaginal mucosa) 
(Hauptstein et al., 2013). The mucus gel, also known as mucin in mucosal membrane 
consists of 95% water and 5% mucus glycoproteins. The mucus layer protects the 
epithelial cells surface against infections. In addition, it also acts as a selective physical 
barrier between the plasma membrane of the epithelial cells with the environments 
(Davidovich-pinhas and Bianco-peled, 2011).  
 
As mentioned earlier, the increase of residence time for drugs to contact with mucosa 
membrane would improve the absorption of drugs at the target site (Singh and Khanna, 
2012). The polymers and mucin interaction is basically based on the formation of non-
covalent bonds such as hydrogen bonds, van der Waal’s forces, and ionic interactions. 
These interactions are categorised as having weak adhesion properties. Therefore, to 
improve the adhesive interaction, the conjugation of polymers with other functional 
groups are further investigated (Sharma and Ahuja, 2011).  
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2.6.1 Alginate 
 
Alginate (Figure 2.2) is a natural polysaccharide obtained from the cell wall of brown 
algae seaweed of Macrocystis pyrifera, Laminaria hyperborea, Laminaria digitata, 
Laminaria japonica, Sargassum vulgare (Masuelli and Illanes, 2014) and Ascophyllum 
nodosum. There are also alginates originated from bacteria such as Azotobacter and 
Pseudomonas species, however, they are very limited and only suitable for small scale 
research studies (Goh et al., 2012). The alginate is widely used in textile, food, paper 
and cosmetics (Masuelli and Illanes, 2014). This polymer functions as an emulsion 
thickener, carrier matrix, wound dressing and agent against heartburn and gastric 
reflux in pharmaceutical and biomedical (Hauptstein et al., 2015).  
 
 
Figure 2.2: The structure of alginate. 
 
In 1980, the first alginate particles were developed for drug encapsulation and many 
studies have been conducted on drug delivery since then (Paques et al., 2014). Alginate 
is good in biocompatibility, higher degree of aqueous solubility, non-immunogenicity 
(Zhao et al., 2015), low toxicity and possible for chemical modification. The mild 
gelatine characteristic of alginate forms when the alginate binds selectively with 
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certain multivalent cations such as sodium, potassium (Sosnik, 2014), calcium, barium 
and strontium (Zhao et al., 2012).  In addition, the presence of calcium ions in alginate 
polymer helps to form nanoparticles (Pawar and Edgar, 2012).   
 
Alginate consists of linear β-d-mannuronic acid (M block) and α-l-gluronic acid (G 
block) which are combined to form 1,4-glycosidic linkages (Chang et al., 2012). The 
M block segments show linear and flexible conformation whereas the G block 
segments act diversely by giving rise to glycosidic linkages and assist in steric 
hindrance around the carboxyl group. Therefore, the G block segments provide folded 
and rigid structural conditions of the alginate molecular chains (Yang et al., 2011).  
The source and methodology used for algae extraction cause the diverge ratio between 
both subunits in biosynthesis of alginates (Bubenikova et al., 2012 ; Zhao et al., 2012).  
  
The calcium alginate showed promising result in drug delivery with more than 90% of 
5-fluorouracil was released at the colon target site (Agarwal et al., 2015). As an anionic 
polymer, alginate has the capability to form hydrogen bonds with mucin type of 
glycoprotein (mucus layer of epithelial cells) from carboxyl and hydroxyl groups in 
the alginate. This interaction has made alginate as a popular choice for 
biotechnological and pharmaceutical applications (Davidovich-pinhas and Bianco-
peled, 2011).   
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2.6.2 Structural modifications of alginate  
 
The alginate consists of numerous free hydroxyl and carboxyl groups distributed along 
the backbone of its polymer chain. These functional groups make alginate to be 
vulnerable to various chemical modifications (Masuelli and Illanes, 2014). The 
properties of alginates are improved by modifying the chemical moiety for solubility, 
hydrophobicity, physicochemical and biological characteristics. There are several 
reported methodologies involved in alginate synthesis such as oxidation, sulfation, 
esterification, amidation or grafting methods. All of the alginate derivatives have good 
potential in the biomedical fields (Yang et al., 2011).   
 
The important points in designing alginate derivatives are solubility, reactivity and 
characterisation. In its native form, alginate is insoluble with mixed salt of the cations 
in seawater (Masuelli and Illanes, 2014). The choice of solvents in extraction process 
determines the chemical modification in aqueous, organic or mixed aqueous-organic 
media. The degree of solubility for alginate brings an impact to derivative substitution 
pattern (Pawar and Edgar, 2012). The reactivity of alginate is based on chemical 
modification of hydroxyl or carboxyl functional group. For hydroxyl group (OH), 
there are two positions available for chemical modification to occur; C-2 or C-3 and 
at C-6 for carboxyl group (COOH) (Pawar and Edgar, 2012). The hydrophilic and 
hydrophobic properties of alginate also could be adjusted by protonation and 
deprotonation of carboxyl groups (Yang et al., 2011). The range and patterns of β-d-
mannuronic acid (M) and α-l-guluronic acid (G) ratios affect the characteristics too 
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(Pawar and Edgar, 2012). The standard ratio between  M and G block is 2:1 where the 
M block is hydrophilic while G block is hydrophobic (Masuelli and Illanes, 2014). 
 
2.7   Disulphide cross-linked in polysaccharide polymers  
 
Disulphide bond is formed from the coupling of two or more thiols. To date, disulphide 
polymers have received much interest in the study related to colon drug delivery due 
to its stability (Zhao et al., 2015) and resistant in the upper GI tract but susceptible to 
degrade at colon region due to low reduction potential environment (Lau and Lim, 
2016). Furthermore, the higher level of GSH as reducing agent in cancer cells also 
provides a conducive environment for the degradation of disulphide cross-linked 
polymers (Chang et al., 2012 ; Gao et al., 2014 ; Gao et al., 2017). 
 
The chemically modified polymers with sulfhydryl (thiol) groups are considered to 
have higher adhesive property compared to mucoadhesive polymers (Davidovich-
pinhas et al., 2009). It is due to the formation of disulphide bonds through covalent 
linking between the thiolated polymers (thiomers) with the cysteine subdomains of 
mucus glycoproteins at mucus membrane (Kast et al., 2001; Davidovich-pinhas and 
Bianco-peled, 2011). The formation of covalent bond may improve the 
‘Pharmaceutical Glue’ in delivery of drug to the target site (Jindal et al., 2010). As a 
result, this condition reduces the dose of drugs used as it localises the polymers to the 
target site (Sharma and Ahuja, 2011). It is also believed to prolong the residence time 
for drug polymer formulations to assemble at the mucosal surface (Davidovich-pinhas 
and Bianco-peled, 2011) and therefore, enhances the cellular permeation at the target 
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site  (Palmberger et al., 2015).  For this reason, further studies are needed to explore 
the advantages of thiomers in modifying the polysaccharides as the selective carrier in 
drug delivery system.  
 
2.8 Strategies of disulphide cross-linked polymers in colon drug delivery 
 
Based on the distinctive physiological properties of the colon, many strategies have 
been developed to fit the colon targeted drug delivery. Several approaches have been 
reported include pH-responsive, time-dependent, pressure dependent, bacterial 
degradation and reduction response drug delivery system (Chang et al., 2012). All 
these approaches have good potential in delivering the selected drugs to the target site. 
Furthermore, optimisation of the physicochemical properties like size, surface charges, 
and the conjugation to some ligands binding to the receptors on the target cells are the 
additional factors that contribute to the accomplishment of this strategy (Koo et al., 
2013).   
 
 
2.8.1 pH-responsive system 
 
In the recent years, more research have been conducted on the pH-responsive polymers 
in drug delivery due to changing pH values in distinctive regions of the GIT (Kocak et 
al., 2017). The pH in the colon cancer cells is lower compared to the normal and 
healthy cells. According to Gao et al. (2014), the environment in cancerous endosomes 
and lysosomes are slightly acidic (pH 5.0 to 6.5 and pH 4.5 to 5.0 respectively) 
compared to the environment in the normal cells. The slightly acidic environment in 
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the colon cancer cells is an ideal condition to stimulate the selective release of anti-
cancer drugs.  
 
The concept of pH responsive delivery was designed based on the ionisable transitions 
property of the nanocarrier to give a good respond towards its environment  (Beloqui 
et al., 2014 ; Kocak et al., 2017). The pH responsive nanocarriers are also able to 
control the drug release by retaining the ionisable groups like carboxylic and amino 
groups. Weak and stable interactions are formed within the structure of the carrier. 
Weak interaction refer to the hydrogen bond and electrostatic interactions between the 
molecules in the nanocarries. This interaction is easily broken and causes serious drug 
leakage in the circulation. On the other hand, the stable interaction is formed by 
chemical cross linked which is difficult to get a good responsive degree due to its 
immovability. However, this interaction shows poor selectivity to tumour cells (Gao 
et al., 2014).  
 
Previous study stated that both calcium alginate and carboxymethyl cellulose hold 
unique properties in having anionic surface charge due to the presence of carboxylic 
groups. This condition allows both polymers to shrink and swell after exposing to 
acidic and basic environment. Both of these polymers showed good sensitivity towards 
different pH environments and this criteria meet the requirement in the delivery of 
drug through the GI tract (Agarwal et al., 2015). In addition, Gao et al., (2014) 
suggested that the disulphide cross-linked in carboxymethyl cellulose shows a good 
potential in controlling the methotrexate release profile with the presence of 
gluthathione, a reducing agent in cancer cells.  
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2.8.2 Bacterial degradation system 
 
Colon is a suitable place for anaerobic bacteria such as Bacteroides, Bifidobacteria, 
Eubacteria, Clostridia, Enterococci, Enterobacteria and Ruminococcus. These 
microflora bacteria obtain their nutrient from the fermentation of undigested food in 
the small intestine (Tiwari et al., 2010). The polysaccharides get a lot of attention for 
colon targeted drug delivery because of their ability to degrade by colonic microflora 
into simple saccharides. These biodegradable polymers are able to activate the 
microflora anaerobic systems to break the glycosidic linkages in the polymers 
(Cummings and Macfarlane, 1991; Smitha et al., 2013). 
 
The microbially triggered strategy has been reported as one of the popular methods in 
colon targeted delivery (Tiwari et al., 2010). High number of bacteria populations in 
the human colon are able to create a reductive environment for chemical bonds like 
azo (Prasanth et al., 2012) and disulphide bonds (Saphier et al., 2012; Lau and Lim, 
2016). Further this, the abundance of enzymes (glucoronidase, xylosidase, 
arabinosidase, galactosidase, nitroreductase, azareducatase, deaminase and urea 
dehydroxylase) produced by the normal microflora in the colon are able to assist the 
bacterial degradation for colon targeted drug delivery (Prasanth et al., 2012).   
 
The tricarballylic acid based disulphide cross-linked polymer is able to retain and 
maintain in harsh GI tract conditions. This study demonstrated high thiol 
concentrations present in colon simulated media from the disintegration of branched 
disulphide cross-linked polymers by Bacteroides fragilis. This finding concludes that 
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the thiol-based polymer is able to withstand the GI tract and only can be cleaved in 
reducible environment at the colon with the presence of bacteria (Lau and Lim, 2016). 
 
2.8.3 Reduction responsive system 
 
The  reduction responsive stimuli has gained much attention as smart drug delivery in 
nano platform for colon drug delivery system (Liu et al., 2016).  Besides the different 
pH in the GI tract, there is significant reductive potential between intracellular and 
extracellular of the cancer site. Glutathione (GSH) is an important reducing agent in 
the human body (Zhao et al., 2015). The concentration of GSH in the cytoplasm 
(intracellular) and plasma (extracellular) are 1-10 mM and 10 µM respectively (Huang 
et al., 2015). The concentration of GSH in the cancer cells is 100 to 500 fold higher 
than the normal cells. Therefore, by utilising the difference between the normal and 
pathological site, the selected carrier would be able to control the release of drug at the 
specific target site (Huang et al., 2013; Gao et al., 2014; Liu et al., 2016).  
 
Nearly 99% of all bacteria species are found in the proximal small intestine to distal 
colon (Tiwari et al., 2010 ; Sreelatha and Brahma, 2013). The expression of total 
metabolic and enzyme activity changes the pH in GI tract. The reduction potentials of 
the proximal and distal small intestines are between −67 mV and −196 mV 
respectively whereas −415 mV at the ascending colon showing the lowest redox 
potential for colon. The disulphide cross-linked polymers are referred to reduction 
sensitive polymers because they could be reversibly cleaved by low reduction potential 
in the colon (Lau and Lim, 2016) with the standard reduction potential of ~250 mV 
for disulphide bonds (Chang et al., 2012). 
